V600EBRAF突变晚期结直肠癌中突触素表达识别预后更差的新亚组
该多机构研究对159例V600EBRAF突变转移性结直肠癌进行突触素免疫组化评估,按高/低表达二分。22.0%的肿瘤任何水平阳性,11.3%在至少20%肿瘤细胞中阳性。多因素分析显示高突触素表达是PFS(HR=2.00,95%CI 1.21-3.33,p=0.006)和OS(HR=2.27,95%CI 1.35-3.85,p=0.001)的独立负性预后因素。
要点
- V600EBRAF突变mCRC中11.3%肿瘤在≥20%细胞表达突触素。
- 高突触素表达是PFS和OS的独立负性预后因素。
- 突触素阳性肿瘤中61.1%为NOS,22.2%为黏液腺癌。
核心结论
- 在V600EBRAF突变转移性结直肠癌中,突触素阳性肿瘤具有更差的PFS和OS。
研究设计与样本
- 多机构系列研究,纳入159例V600EBRAF突变转移性结直肠癌,匹配临床和病理信息。
- 采用免疫组化评估突触素表达,将肿瘤二分为高表达和低表达。
- 采用Kaplan-Meier法和log-rank检验评估总生存期和无进展生存期。
主要发现
- 35例肿瘤(22.0%)显示任何水平突触素阳性,18例(11.3%)在至少20%肿瘤细胞中阳性。
- 4例肿瘤100%突触素阳性。
- 突触素阳性(≥20%)肿瘤中,11例(61.1%)组织学类型为非特殊型,4例(22.2%)为黏液腺癌。
- 4例(22.2%)为DNA错配修复缺陷,7例(38.9%)肿瘤浸润淋巴细胞数量高。
- 多因素分析显示,高突触素表达是PFS(HR=2.00,95%CI 1.21-3.33,p=0.006)和OS(HR=2.27,95%CI 1.35-3.85,p=0.001)的独立负性预后因素。
临床怎么用
- 对V600EBRAF突变转移性结直肠癌可考虑评估突触素表达以辅助预后分层。
- 高突触素表达提示预后更差,或可支持更密切的随访或强化治疗决策。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neuroendocrine differentiation has been extensively associated with worse prognosis and to mechanisms of therapy resistance in several epithelial cancers. A high prevalence of neuroendocrine differentiation was recently described in V600EBRAF-mutated (BRAFmt) metastatic colorectal cancers (mCRCs) but no data are available about its prognostic impact in this setting. METHODS: We assessed synaptophysin immunohistochemical expression in a multi-institutional series of 159 BRAFmt mCRCs with matched clinical and pathological information. Tumours were dichotomized as synaptophysin high and low. Overall survival (OS) and progression-free survival (PFS) were evaluated by Kaplan-Meier and log-rank tests. RESULTS: Thirty-five tumours (22.0%) showed any level of positivity for synaptophysin, and 18 (11.3%) were characterized by positivity in at least 20% of tumour cells. Four cases resulted 100% synaptophysin positive. The histotype of synaptophysin-positive tumours (i.e. ≥20%) was not otherwise specified in 11 cases (61.1%) and mucinous adenocarcinoma in 4 cases (22.2%). Four cases were DNA mismatch repair deficient (22.2%) and 7 (38.9%) were characterized by a high number of tumour-infiltrating lymphocytes. At multivariate analysis, high synaptophysin expression was a negative independent prognostic factor for both PFS (HR = 2.00, 95% confidence interval [CI] 1.21-3.33, p = 0.006) and OS (HR = 2.27, 95% CI 1.35-3.85, p = 0.001). CONCLUSIONS: Among BRAFmt mCRCs, synaptophysin-positive tumours are characterized by worse PFS and OS. Further studies should investigate the molecular mechanisms involved in the acquisition of the neuroendocrine phenotype to identify novel-targeted treatment strategies.
引用
- Fassan M, Milione M, Maddalena G, et al. Synaptophysin expression in V600EBRAF-mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. Eur J Cancer. 2021. PMID: 33607478. doi:10.1016/j.ejca.2021.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。